Efficacy of topical immunoglobulins against experimental adenoviral ocular infection

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 9, 2007, Pages 4171-4176

  Nwanegbo, Edward C ^a   Romanowski, Eric G ^a   Gordon, Y Jerold ^a   Gambotto, Andrea ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; SODIUM CHLORIDE; ANTIVIRUS AGENT; CYTOSINE; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; PHOSPHONIC ACID DERIVATIVE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIUM CELL; EYE INFECTION; EYE TOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; SEROTYPE; VIRUS REPLICATION; ANIMAL; CONJUNCTIVA; CORNEA; CULTURE TECHNIQUE; DISEASE MODEL; DRUG EFFECT; FLOW CYTOMETRY; HUMAN ADENOVIRUS; ISOLATION AND PURIFICATION; KERATOCONJUNCTIVITIS; PHYSIOLOGY; RABBIT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VIRAL EYE INFECTION; VIROLOGY; VIRUS CULTURE; VIRUS INFECTION; VIRUS SHEDDING;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; CONJUNCTIVA; CORNEA; CYTOSINE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; EYE INFECTIONS, VIRAL; FLOW CYTOMETRY; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KERATOCONJUNCTIVITIS; PHOSPHONIC ACIDS; RABBITS; TREATMENT OUTCOME; VIRUS CULTIVATION; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 35148859697     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0491     Document Type: Article

References (39)

1. Gordon JS, Aoki K, Kinchington PR. Adenovirus keratoconjunctivitis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity: St. Louis: Mosby; 1996;877-894.
2. Kinchington PR, Turse SE, Kowalski RP, Gordon YJ. Use of polymerase chain amplification reaction for detection of adenoviruses in ocular swab specimens. Invest Ophthalmol Vis Sci. 1994;35:4126-4134.
3. Gordon JS. Adenoviruses and other nonherpetic viral diseases. In: Smolin G, Thoft RA, eds. The Cornea. 3rd ed. Boston: Little, Brown and Co.; 1994;215-227.
4. Piednoir E, Bureau-Charlot F, Merle C, Gotzamanis A, Wuibout J, Bajolet O. Direct costs associated with a nosocomial outbreak of adenoviral conjunctivitis infection in a long-term care institution. Am J Infec Control. 2002;30:407-410.
5. Dart JK. Eye disease at a community health center. BMJ. 1986;293:1477-1480.
6. McDonnell PJ. How do general practitioners manage eye disease in the community? Br J Ophthalmol. 1988;72:733-736.
7. Barnard DL, Hart JCD, Marmion VJ, Clarke SKR. Outbreak in Bristol of conjunctivitis caused by adenovirus type 8, and its epidemiology and control. BMJ. 1973;2:165-169.
8. Kanski JJ. Clinical Ophthalmology. 3rd ed. Boston: Butterworth-Heinemann; 1998;86.
9. Trousdale MD, Nobrega R, Wood RL, et al. Studies of adenovirus-induced eye disease in the rabbit model. Invest Ophthalmol Vis Sci. 1995;36:2740-2748.
10. Everitt H, Little P. How do GPs diagnose and manage acute infective conjunctivitis? - a GP survey. Fam Pract. 2002;19:658-660.
11. Rose WP, Harnden A, Brueggemann AB, Perera R, Sheikh A, Crook D, Mant D. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomized double-blind placebo-controlled trial. Lancet. 2005;366:37-43.
12. Ward JB, Siojo LG, Waller SG. A prospective, masked clinical trial of trifluridine, dexamethasone and artificial tears in the treatment of epidemic keratoconjunctivitis. Cornea. 1993;12:216-221.
13. Hutter H. Epidemic keratoconjunctivitis: treatment results during an epidemic (in German). Klin Monatsbl Augenheilkd. 1990;197:214-217.
14. Gordon YJ, Araullo-Cruz T, Romanowski EG. The effects of topical NSAIDs on adenoviral replication. Arch Ophthalmol. 1998;116:900-905.
15. Kaufman HE. Treatment of viral diseases of the cornea and external eye. Prog Retin Eye Res. 2000;19:69-85.
16. Romanowski EG, Yates KA, Teuchner B, Nagl M, Irschick EU, Gordon YJ. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model. Invest Ophthalmol Vis Sci. 2006;47:2021-2026.
17. Epstein SP, Pashinsky YY, Gershon D, et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmol. 2006;6:22.
18. Liesegang TJ. Use of antimicrobials to prevent postoperative infection in patients with cataracts. Curr Opin Ophthalmol. 2001;12:68-74.
19. Isenberg SJ, Apt L, Valenton M, et al. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children, Am J Ophthalmol. 2002;134:681-688.
20. Martin T, Duffy SF, Carson DA, Kipps TJ. Evidence for somatic selection of natural autoantibodies. J Exp Med. 1992;175:983-991.
21. de Gracia J, Vendrell M, Guarner L, et al. The use of human gammaglobulin in the treatment of common variable immunodeficiency. Med Clin Barc. 1995;104:201-206.
22. Galli E, Barbieri C, Cantani A, Solano A, Longhi MA, Businco L. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: clinical and immunologic follow-up. Ann Allergy. 1990;64:147-150.
23. Baker CJ, Rench MA, Noya FJ, Garcia PJ. Role of intravenous immunoglobulin in prevention of late-onset infection in low-birthweight neonates. The Neonatal IVIG Study Group. Rev Infect Dis. 1990;12:S463-S469.
24. Hague RA, Eden OB, Yap PL, Mok JYQ, Rae P. Hyperviscosity in HIV infected children: a potential hazard during intravenous immunoglobulin therapy (in German). Blut. 1990;61:66-67.
25. Ascher DP, Laws HF, Hayes CG. The use of intravenous gammaglobulin in dengue fever: a case report. Southeast Asian J Trop Med Public Health. 1989;20:549-554.
26. Bayry J, Misra J, Latry N, et al. Mechanisms of action of intravenous immunoglobulins in autoimmune and inflammatory diseases. Transfusion Clin Biol. 2003;10:165-169.
27. Schenkein DP. Intravenous IgG for treatment of autoimmune disease. Hosp Pract Off Ed. 1992;7:29-36.
28. Hurez V, Kaveri SV, Kazatchkine MD. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. J Autoimmun. 1993;6:675-681.
29. Gold H, Hartung HP, Toyka KV. Therapy with immunoglobulins in neurologic autoimmune diseases: indications and mechanism of action (in German). Fortschr Neurol Psychiatr. 1995;63:17-29.
30. The Dutch Guillain-Barre Study Group. Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol. 1994;35:749-752.
31. Goossens PH, Vogels R, Piteterman E, et al. The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. Arthritis Rheum. 2001;44:48-52.
32. Toogood C, Crompton J, Hay R. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol. 1992;73:1429-1435.
33. Lenaerts L, Naesens L. Antiviral therapy for adenovirus infections. Antiviral Res. 2006;71:172-180.
34. Gordon YJ, Romanowski E, Araullo-Cruz T. An ocular model of adenovirus type-5 infection in the NZ rabbit. Invest Ophthalmol Vis Sci. 1992;33:574-580.
35. Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model. Invest Ophthalmol Vis Sci. 2001;42:1812-1815.
36. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004;11:351-357.
37. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis. Pediatrics. 1998;101:1013-1019.
38. Draize JH, Woodward G, Calvery HO. Methods for the study of irritation and toxicity of articles applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377-390.
39. Kay JH, Calandra JC. Interpretation of eye irritation tests. J Soc Cos Chem. 1962;13:281-289.